Pfizer’s Low-Dose Covid-19 Vaccine Fails In Less Than 5 Children, Tests

Today it has brought heartbreaking news to parents in the US hoping to soon vaccinate their young children in COVID-19. Based on clinical research, Pfizer and BioNTech he announced On Friday that children between the ages of 2 and 5 did not develop adequate immunity to their low-dose Covid-19 vaccine, although children between 6 months and 2 years of age were exposed.

Companies are now planning to increase their testing by adding a minimum third-degree rate to the program, both for this age group and for children ages 5 to 12. They will have to wait until the first half of next year.

The Pfizer / BioNTech case affected more than 4,500 children between the ages of six and 11 months in the US, Finland, Poland, and Spain. Over 5-year-olds were given 10 micrograms of vaccine (one-third of the adult dose) in a two-day dose program 21 days apart, while those under 5 years were given a 3-microgram dose per shot.

Late October, the FDA allowed Pfizer / BioNTech vaccine for children aged 5 to 11 years. in younger adults already. Unfortunately, the immune response was not adequate for vaccinated children aged 2 to 4, Pfizer / BioNTech said Friday, based on a temporary data analysis.

This failure to delay any vaccination program for these groups. Although children between the ages of six months and 2 years were considered to have strong immune systems, companies have made the decision (with the blessings of the authorities) to develop this study for all children under 5 years of age. They will now receive a third level of 3 micrograms at least two months after the second dose. The companies have also announced plans to study the third level of 10 micrograms for children 5 to 11, as well as 12 to 17 young people. (EUA) in the first half of 2022.

G / O Media can find a job

Save $50

Eufy Security Smart Lock

Lock and unlock your door from anywhere
It locks automatically when the sensor notices the door is closed, has a BHMA Grade 2 security certification, and works after more than 250,000 uses.

The decision to use lower doses for children was predicated on the hope that it would provide similar protection as the adult shots, while lessening any potential side effects, in particular the increased but rare risk of heart inflammation (myocarditis) that has been seen in teens and young adults, moreso in males than females. So far, at least, there none has shown significant safety implications for children aged 5 to 11. The CDC has identified eight cases of myocarditis among the age group after vaccination, although it did not say whether the cases were linked to vaccination. All cases appear to be minor and at least five have already recovered, According to the CDC.

But recent findings suggest that it can be difficult to find the right dose and to prepare a vaccine, of all ages. Considering research showing that the immune system has begun to decline with vaccines by two doses, as well as the emergence of various species such as Delta and Omicron now, many scientists and health officials have taken action. began ordering an mRNA vaccine to be identified as a triple vaccine, not a two-way vaccine. And this seems to be the way Pfizer / BioNTech is going.

At a press conference Friday, The New York Times he said, Kathrin Jansen, Pfizer’s chief vaccine researcher, made it clear that the company wants its vaccine to be approved as a three-pronged approach for children. And when that happens, it may open the way for that to happen again to groups of all ages.

Numerous studies have shown that people who are given Three Doses appear to have a stronger immune system from Delta and possibly Omicron, although there is a question of how long it takes to strengthen the immune system.